The NICE British National Formulary (BNF) and British National Formulary for Children (BNFc) sites are only available to users in the UK, Crown Dependencies and British Overseas Territories. If you believe you are seeing this page in error please contact us. From 1 October 2017, eligible people will be able to receive funded access to ciprofloxacin 0.3% eye drops for use in ears for the second line treatment of chronic suppurative otitis media (middle ear infection with perforated membrane). This was the subject of an amended consultation letter dated 14 August 2017. We have since made minor changes to the wording of the restriction for administrative purposes, however the intent remains unchanged. Subsidy by endorsement When prescribed for the treatment of bacterial keratitis or severe bacterial conjunctivitis resistant to chloramphenicol; or for the second line treatment of chronic suppurative otitis media (CSOM)*; and the prescription is endorsed accordingly. Notes: Indication marked with a * is an Unapproved Indication. This decision will not change the listing in Section H of the Pharmaceutical Schedule for ciprofloxacin 0.3% eye drops. We note that ciprofloxacin 0.3% eye drops are not registered by Medsafe for the second line treatment of CSOM; therefore, in this setting it would need to be prescribed and used in accordance with section 25 of the Medicines Act 1981.
What are the possible side effects of ciprofloxacin ophthalmic Ciloxan. Ciprofloxacin eye drops solution are not approved for use by anyone younger than. Ciprofloxacin eye drops and eye ointment are used to treat infections of the eye, such as bacterial conjunctivitis. Ciprofloxacin eye drops is also used to treat.